Cellectis SA (ADR) (CLLS) Just Made A Big Step Forward In CAR-T

Cellectis SA (ADR) (NASDAQ:CLLS) just announced that the FDA has granted it approval to proceed with the clinical development of a drug called UCART123.

Keep Reading →